Date | Price Target | Rating | Analyst |
---|---|---|---|
9/9/2024 | $37.00 | Buy | H.C. Wainwright |
6/11/2024 | $32.00 | Outperform | Robert W. Baird |
4/9/2024 | $34.00 | Buy | Mizuho |
3/29/2023 | $27.00 | Buy | Jefferies |
3/3/2023 | Outperform | TD Cowen |
BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic. ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target th
Dosed the first patient in the Phase 1b arm of the clinical trial evaluating ELVN-001 in patients with CML that is relapsed, refractory or intolerant to available TKIs Dosed the first patient in the Phase 1a clinical trial evaluating ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ MBC and CRC Strong balance sheet with $312 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generat
BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June: Jefferies Global Healthcare ConferenceFormat: Fireside ChatDate: Wednesday, June 5Time: 8:30 a.m. ET Goldman Sachs Annual Global Healthcare ConferenceFormat: Fireside ChatDate: Monday, June 10Time: 3:20 p.m. ET Both fireside chats will be webcast live and can be accessed by visiting the investor relations section of the Company's website at https://ir.enliventh
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)
10-Q - Enliven Therapeutics, Inc. (0001672619) (Filer)
8-K - Enliven Therapeutics, Inc. (0001672619) (Filer)
144 - Enliven Therapeutics, Inc. (0001672619) (Subject)
H.C. Wainwright initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $37.00
Robert W. Baird initiated coverage of Enliven Therapeutics with a rating of Outperform and set a new price target of $32.00
Mizuho initiated coverage of Enliven Therapeutics with a rating of Buy and set a new price target of $34.00
Baird analyst Colleen Kusy initiates coverage on Enliven Therapeutics (NASDAQ:ELVN) with a Outperform rating and announces Price Target of $32.
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.57) by 5.26 percent.
Thursday, Enliven Therapeutics Inc (NASDAQ:ELVN) released proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs). ELVN-001 is a small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with CML. “We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, Chief Medical Officer of Enliven. Related Co
SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board. "Lori has served as scientific advisor to Enliven since its inception, and we are delighted to now welcome her to our Board," said Sam Kintz, MBA, Enliven's Co-founder and Chief Executive Officer. "She brings a wealth of e